Nicholas Augustinos - 28 May 2026 Form 4 Insider Report for DEXCOM INC (DXCM)

Reporting relationship: Director
Issuer ticker: DXCM
Reported as of: 28 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 01 Jun 2026, 17:34:59 UTC
Prior SEC filing: 11 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Jereme M. Sylvain, as Attorney-in-Fact for Nicholas Augustinos

Key filing fact

Nicholas Augustinos filed Form 4 for DEXCOM INC (DXCM) on 01 Jun 2026.

Key facts

This page summarizes Nicholas Augustinos's Form 4 filing for DEXCOM INC (DXCM).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 01 Jun 2026, 17:34.

Change

Previous filing in this sequence was filed on 11 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001238485 Primary reporting owner

AUGUSTINOS NICHOLAS

Relationship: Director
Address: 6340 SEQUENCE DRIVE, SAN DIEGO
Signature: /s/ Jereme M. Sylvain, as Attorney-in-Fact for Nicholas Augustinos
Signature date: 01 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

DXCM transaction

Common Stock

Award

Transaction value
Shares: +5,575
Change %
Price: $0.000000^*
Shares after: 5,575
Date: 28 May 2026
Ownership: Direct
Footnotes: F1

DXCM holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 38,457
Date: 28 May 2026
Ownership: by Trust
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The RSU Award was granted on May 28, 2026 and 100% of the RSU Award will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement.

Footnote F2

Shares are held by the Kirschner/Augustinos Revocable Trust, with respect to which the Reporting Person is a trustee.